BMAL1 and myocardial ischemia: For example, one study used CRISPR/Cas9-mediated gene editing technology to generate BMAL1-deficient human stem cells and a non-human primate research model, through which the application of the model revealed that the core rhythmic protein BMAL1 has the novel function of maintaining genome stability, inhibiting transposon LINE1 activation, and antagonizing the aging of primate tissues and cells [87], which provides a new model and new technology for the mechanism of BMAL1 research and provides new models and techniques that may be applied to myocardial ischemia research in the future.